

Modelling the CD8⁺ T cell immune response to heterogeneous tumours

Emma Leschiera Supervised by: Luis Almeida, Chloe Audebert, Tommaso Lorenzi

June 22, 2021 - SMAI 2021

Laboratoire Jacques Louis Lions - Sorbonne Université (Paris)

Mathematical model

Numerical simulations and biological implications

Conclusion





Adapted from: Fennemann et al. [2019]

Mathematical model

THE MODEL:

- $\cdot \,$ Individual-based model: 1 cell \rightarrow 1 agent
- · Cell behaviours and interactions: rules with probabilities
- · 2D model
- $\cdot\,$ Two cell types: tumour cells and CD8 $^+$ T cells

THE MODEL:

- + Individual-based model: 1 cell \rightarrow 1 agent
- Cell behaviours and interactions: rules with probabilities
- 2D model
- $\cdot\,$ Two cell types: tumour cells and CD8+ T cells

TUMOUR CELLS:

- \cdot 1/+ antigens
- · Antigens: clonal or sub-clonal



THE MODEL:

- + Individual-based model: 1 cell \rightarrow 1 agent
- 2D model
- · Cell behaviours and interactions: rules with probabilities
- $\cdot\,$ Two cell types: tumour cells and CD8+ T cells

TUMOUR CELLS:

- 1/+ antigens
- Antigens: clonal or sub-clonal
- \cdot Sub-populations of tumour cells
- · Antigens: presented at different levels





THE MODEL:

- Individual-based model: 1 cell \longrightarrow 1 agent
- 2D model
- Cell behaviours and interactions: rules with probabilities
- $\cdot\,$ Two cell types: tumour cells and CD8+ T cells

TUMOUR CELLS:

- Express 1/+ antigens
- Antigens: clonal or sub-clonal
- Sub-populations of tumour cells
- Antigens: presented at different levels
- Mitosis



CD8⁺ T CELLS:

• 1 TCR specific to 1 antigen



 $\mathsf{CD8^+}\ \mathsf{T}\ \mathsf{CELLS}$:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells





 $\mu: \propto$ level of antigen presentation



 $\mu: \propto$ level of antigen presentation \Rightarrow immunogenic cells: killed more easily than non-immunogenic cells

$CD8^+$ T CELLS:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells

CHEMOATTRACTANT(S):

• Cytokines and signalling proteins able to induce directed chemotaxis of CD8⁺ T cells toward their targets

$CD8^+$ T CELLS:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells

- Cytokines and signalling proteins able to induce directed chemotaxis of CD8⁺ T cells toward their targets
- Secreted by tumour cells

CD8⁺ T CELLS:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells

- Cytokines and signalling proteins able to induce directed chemotaxis of CD8⁺ T cells toward their targets
- \cdot Secreted by tumour cells
- As many chemoattractants as antigens expressed by the tumour

$CD8^+$ T CELLS:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells

- Cytokines and signalling proteins able to induce directed chemotaxis of CD8⁺ T cells toward their targets
- Secreted by tumour cells
- As many chemoattractants as antigens expressed by the tumour
- $\cdot \;$ Secretion: \propto level of antigen presentation

CD8⁺ T CELLS:

- 1 TCR specific to 1 antigen
- Chemotactic movement toward tumour cells expressing the matching antigens
- Interaction with tumour cells

- Cytokines and signalling proteins able to induce directed chemotaxis of CD8⁺ T cells toward their targets
- Secreted by tumour cells
- As many chemoattractants as antigens expressed by the tumour
- Secretion: \propto level of antigen presentation
- $\cdot\,$ Influx of T cells: \propto total amount of chemoattractants

Initial conditions

Inspired by: Wolf et Al. Uvb-induced tumor heterogeneity diminishes immune response in melanoma. *Cell*, 2019.

• Tumour-3a: 3 antigens \rightarrow 1 clonal (5) and 2 sub-clonal (4 and 7)



Initial conditions

Inspired by: Wolf et Al. Uvb-induced tumor heterogeneity diminishes immune response in melanoma. *Cell*, 2019.

- Tumour-3a: 3 antigens \rightarrow 1 clonal (5) and 2 sub-clonal (4 and 7)
- Tumour-7a: 7 antigens \rightarrow 2 clonal (1 and 5) and 5 sub-clonal (4, 6, 7, 8, 10)



Numerical simulations and biological implications

2 possible outcomes:

- $\rightarrow \text{immune clearance}$
- ightarrow immune escape

2 possible outcomes:

- ightarrow immune clearance
- ightarrow immune escape

<u>Goal</u>: investigate the effects of ITH by varying:

2 possible outcomes:

- ightarrow immune clearance
- ightarrow immune escape

<u>Goal</u>: investigate the effects of ITH by varying:

1. the number of antigens (*i.e.* the number of sub-populations) constituting the tumour

2 possible outcomes:

- ightarrow immune clearance
- ightarrow immune escape

<u>Goal</u>: investigate the effects of ITH by varying:

- 1. the number of antigens (*i.e.* the number of sub-populations) constituting the tumour
- 2. the immunogenicity of the tumour (*i.e.* the ratio between immunogenic and non-immunogenic cells)

2 possible outcomes:

- ightarrow immune clearance
- ightarrow immune escape

<u>Goal</u>: investigate the effects of ITH by varying:

- 1. the number of antigens (*i.e.* the number of sub-populations) constituting the tumour
- 2. the immunogenicity of the tumour (*i.e.* the ratio between immunogenic and non-immunogenic cells)
- 3. both the number of antigens AND the immunogenicity of the tumour

Results(1)

<u>Goal(1)</u>: investigate of the effects of ITH by varying the number of sub-populations constituting the tumour

Wolf et al. [2019]: increasing the number of sub-populations of tumour cells results in less effective immune response and significantly larger tumours



Results(1)

Our results:



— Tumour-3a: 1 sub-population of immunogenic cells and 2 sub-populations of non-immunogenic cells

— Tumour-7a: 2 sub-populations of immunogenic cells and 5 sub-populations of non-immunogenic cells

```
Both tumours: 75% I - 25% NI
```

Results(2)

<u>Goal(2)</u>: investigate of the effects of ITH by varying the immunogenicity of tumour cells (*i.e.* the ratio between immunogenic and non-immunogenic cells)

Inspired by: Gejman et Al. Rejection of immunogenic tumor clones is limited by clonal fraction. *Elife*, 2018

A different ratio between immunogenic (SIIN) and non-immunogenic (FEK) cells influence immune surveillance



Results(2)

Our results:



— Tumour-3a: 1 sub-population of immunogenic cells and 2 sub-populations of non-immunogenic cells

Results(3)

<u>Goal(3)</u>: investigate of the effects of ITH by varying both the number of antigens AND the immunogenicity of the tumour

Wolf et al. [2019]: both the number of sub-populations and the ratio of immunogenic and non-immunogenic cells are responsible of immune escape



Adapted from: Wolf et al. [2019]

Results(3)

Our results:



Conclusion

- Individual-based model for tumour-immune cell interactions

- Individual-based model for tumour-immune cell interactions
- Investigation of the effects of ITH for tumours characterized by:
 - different antigen profiles
 - · different level of immunogenicity

- Individual-based model for tumour-immune cell interactions
- Investigation of the effects of ITH for tumours characterized by:
 - different antigen profiles
 - different level of immunogenicity
- Both the number of sub-populations AND the ratio of immunogenic cells are responsible of immune escape

- Individual-based model for tumour-immune cell interactions
- Investigation of the effects of ITH for tumours characterized by:
 - different antigen profiles
 - different level of immunogenicity
- Both the number of sub-populations AND the ratio of immunogenic cells are responsible of immune escape
- Next steps:
 - $\cdot\,$ role of T cell infiltration on immune response
 - \cdot derivation of a continuum model

Thank you for your attention !

Emma Leschiera

References

- F. L. Fennemann, I. J. M. de Vries, C. G. Figdor, and M. Verdoes. Attacking tumors from all sides: personalized multiplex vaccines to tackle intratumor heterogeneity. *Frontiers in immunology*, 10:824, 2019.
- Y. Wolf, O. Bartok, S. Patkar, G. B. Eli, S. Cohen, K. Litchfield, R. Levy,
 A. Jiménez-Sánchez, S. Trabish, J. S. Lee, et al. Uvb-induced tumor heterogeneity diminishes immune response in melanoma. *Cell*, 179 (1):219–235, 2019.